Evidence map›Paper›PMID 32426145›Full record

ArticleCanadian journal of kidney health and disease2020

Prescription Patterns in Dialysis Patients: Differences Between Hemodialysis and Peritoneal Dialysis Patients and Opportunities for Deprescription.

Judith G Marin, Laura Beresford, Clifford Lo, Alexander Pai, Gabriela Espino-Hernandez, Monica Beaulieu

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Canadian journal of kidney health and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05585268 (Electronic Decision Support for Deprescribing in Patients on Hemodialysis), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05585268 nacompletednot on this mapstarted 2022, after this paper: background citation

Electronic Decision Support for Deprescribing in Patients on Hemodialysis: a Prospective, Controlled, Quality Improvement Study

TypeinterventionalSponsorMcGill University Health Centre/Research Institute of the McGill University Health CentreRan2022 to 2022Enrolled195ConditionsEnd Stage Renal Disease, Hypertension, Diabete Type 2, Renal Failure ChronicArmsMedication reconciliation supplemented with MedSafer and deprescribing brochures
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Inappropriate use of clinical practices in Canada: a systematic review.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Prescribing patterns and medication costs in patients on maintenance haemodialysis and peritoneal dialysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Prescribing and peritoneal dialysis.Australian prescriber · 2023
    Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Judith G MarinSt. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.ORCID https://orcid.org/0000-0001-9317-8809
Laura BeresfordUBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
Clifford LoUBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
Alexander PaiUBC Faculty of Pharmaceutical Sciences, Vancouver, Canada.
Gabriela Espino-HernandezDepartment of Medicine, The University of British Columbia, Vancouver, Canada.
Monica BeaulieuSt. Paul's Hospital, Providence Health Care, Vancouver, BC, Canada.
University of British Columbia Hospital · CAProvidence Health Care · CAUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients treated with maintenance dialysis are at high risk of polypharmacy given their many comorbidities as well as complications from their disease state and treatment. The prescribing patterns and burden of polypharmacy in patients treated with maintenance dialysis, and specifically the difference between hemodialysis (HD) and peritoneal dialysis (PD) prescribing, are not well characterized.

objectivesThe objectives of this study were to review the prescribing patterns for patients treated with maintenance dialysis, to compare prescribing pattern between HD and PD, and to identify opportunities for deprescription.

designThis is a retrospective cohort study.

settingThis study was conducted in all dialysis centers in British Columbia, Canada. PATIENTS: Patients who were receiving chronic dialysis (>120 days on the same dialysis modality) between June 3 and October 1, 2015, and registered in the British Columbia (BC) Renal Patient Records and Outcomes Management Information System. MEASUREMENTS: Patient demographics as well as both prescription and non-prescription medications were collected. Comparison of discrete and continuous variables was made by chi-square analysis and independent

methodsMedications were classified by indication: (1) management of renal complications, (2) cardiovascular (CV) medications, (3) diabetes medications, or (4) management of symptoms, and then classified as to whether they were a "potentially inappropriate medication" (PIM) or not. Ethics approval was granted from the University of British Columbia Research and Ethics Board.

resultsIn total, 3017 patients met inclusion criteria (2243 HD, 774 PD). The mean age was 66.2 ± 14.8 years. The HD group had more patients over 80 years old (22.1% vs 12.5%) and more patients with diabetes and CV disease. The mean number (standard deviation [SD]) of discrete prescribed medications was 17.71 (5.72) overall with more medications in the HD group versus the PD group. The mean number of medications increased with dialysis vintage in both groups. HD patients were on more medications for renal complications and management of symptoms than PD patients. Of the total number of medications prescribed, 5.02 (2.78) were classified as a PIM, with the number of PIMs higher in HD vs PD patients: 5.37 (2.83) versus 4.02 (2.37). LIMITATIONS: In BC, some of the medications are prescribed through standardized protocols and may not be comparable with other Canadian provinces. We report here prescribing patterns, not utilization patterns, as we are not able to ascertain actual consumption of prescribed medication.

conclusionThis study reviews and characterizes both the prescription and non-prescription medication prescribed to HD patients and PD patients in BC. Pill burden in both groups is high, as is the prescription of PIMs. Patients receiving maintenance HD receive more overall medications and more PIMs. These results highlight areas of opportunities for future systematic and patient-informed deprescription initiatives in both patient groups.

Indexed as

deprescriptionend-stage kidney diseasehemodialysismedication safetyperitoneal dialysispolypharmacypotentially inappropriate medication

Identifiers

PMID32426145
PMCPMC7218341
OpenAlexW3020956628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.